Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$331.91 2.87 (0.87)%

High 334.53 Low 326.90 Volume 275,572 Market Cap 35.17B
06/22/18 12:41 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Jun 06

    Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health

    Read on
  • Jun 04

    New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma

    Read on

EVENTS

  • Goldman Sachs 39th Annual Global Healthcare Conference
    Jun 12, 2018 | 8:40 AM PT

  • Corporate Presentation - June 2018
    Jun 12, 2018

Events & Presentations

NASDAQ REGN

$331.91 2.87 (0.87)%

High 334.53 Low 326.90 Volume 275,572 Market Cap 35.17B
06/22/18 12:41 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information